Sangamo Therapeutics
Trial Pipeline
Safety and Tolerability Study of ST-503 for Refractory Pain Due to Peripheral Neuropathy (Small Fiber Predominant, SFN)
NCT06980948
Long - Term Follow Up of Sickle Cell Disease and Beta-thalassemia Subjects Previously Exposed to BIVV003 or ST-400.
NCT05145062
Long Term Follow-up (LTFU) of Subjects Who Received SB-318, SB-913, or SB-FIX
NCT04628871
A Study to Assess the Safety, Tolerability, and Efficacy of BIVV003 for Autologous Hematopoietic Stem Cell Transplantation in Patients With Severe Sickle Cell Disease
NCT03653247
A Study to Assess the Safety, Tolerability, and Efficacy of ST-400 for Treatment of Transfusion-Dependent Beta-thalassemia (TDT)
NCT03432364
Phase 1 Dose Escalation Study of Autologous T-cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Patients
NCT01044654
Safety and Efficacy of CERE-120 in Subjects With Parkinson's Disease
NCT00985517
Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy
NCT00476931
Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy
NCT00406458
CERE-110 in Subjects With Mild to Moderate Alzheimer's Disease
NCT00087789
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 6 |
| Phase 2 | 2 |
What the Pipeline for Sangamo Therapeutics Shows
According to the ClinicalTrials.gov registry, Sangamo Therapeutics is linked to 10 US clinical trials across every stage of research activity. Of those, 1 studies are currently recruiting — about 10% of the sponsor's indexed portfolio — and 7 are already marked complete, representing roughly 70% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.
The phase mix for Sangamo Therapeutics reports 0 late-stage studies (Phase 3 and Phase 4 combined) and 8 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.
The top therapeutic focus area indexed for Sangamo Therapeutics is Diabetic Polyneuropathy with 2 linked trials, and 9 other condition areas appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.
Read our methodology — how this data is sourced, computed, and verified.